You can buy or sell Forty Seven and other stocks, options, ETFs, and crypto commission-free!
Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. Read More The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA.
Menlo Park, California
52 Week High
52 Week Low
Seeking AlphaMar 11
March Outlook For Forty Seven Inc.
On the technical side, FTSV may have hit its trading ceiling (absent of clinical updates) and may be due for a correction unless there's more trial news that's positive.
Stock Price, News, & Analysis for Forty Seven
News articles about FTSV stock have been trending very positive recently, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Forty Seven earned a news impact score of 4.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 8.0 out of 10, indicating that rec...
-$0.65 per share
Expected Mar 25, Pre-Market